| Sep 3 |
Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial
|
| Aug 28 |
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
|
| Aug 8 |
Keros Therapeutics GAAP EPS of -$1.25, revenue of $0.04M
|
| Jul 5 |
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
|
| Jun 25 |
Analyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech Growth
|
| Jun 17 |
Keros Therapeutics appoints Jasbir S. Seehra as Chair of board
|
| Jun 17 |
Keros Therapeutics Announces Leadership Updates
|
| Jun 17 |
Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association
|
| Jun 10 |
Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers
|
| Jun 4 |
Keros Therapeutics to Host a Corporate Update Conference Call and Webcast
|
